Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

Jordi, Bruix,; Jean-Luc, Raoul,; Morris, Sherman,; Vincenzo, Mazzaferro,; Luigi, Bolondi,; Antonio, Craxi,; Peter R, Galle,; Armando, Santoro,; Michel, Beaugrand,; Angelo, Sangiovanni,; Camillo, Porta,; Guido, Gerken,; Jorge A, Marrero,; Andrea, Nadel,; Michael, Shan,; Marius, Moscovici,; Dimitris, Voliotis,; Josep M, Llovet,

doi:10.1016/j.jhep.2012.06.014

Public

Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.

Published in Journal of hepatology • Oct 1, 2012

Authors:

Bruix, Jordi

Raoul, Jean-Luc

Sherman, Morris

Abstract

BACKGROUND & AIMS: The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival and is safe for patients with advanced HCC. In this trial, 602 patients with well-preserved liver function (>95% Child-Pugh A) were rando...

Subject

Aged

Alcoholism

Antineoplastic Agents

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!